Addiction

Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing…

4 months ago

Revive Recovery and Detox Services Clarifies NO AFFILIATION With Revive Premier Treatment Center

LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located…

4 months ago

Silver Pines Treatment Center Achieves PsychArmor Certification as a ‘Veteran Ready’ Organization

BRENTWOOD, TN / ACCESSWIRE / December 5, 2023 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and…

4 months ago

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)…

4 months ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential…

4 months ago

Intrepid Recovery Center Unveils Innovative Partial Hospitalization Program (PHP) in West Palm Beach, Florida

Intrepid Recovery Center's Founder, John Nash Pakel, Champions the Next Phase in Addiction Treatment with the Introduction of PHP -…

4 months ago

BayMark Releases Whitepaper: 2023 Nationwide Opioid Use Disorder Treatment Outcomes Report

BayMark's Study Demonstrates the Path to More Successful Opioid Use Disorder TreatmentLEWISVILLE, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- BayMark,…

4 months ago

Pasadena Villa Outpatient Clinics in McLean and Norfolk, Virginia Are PsychArmor Certified as ‘Veteran Ready’

BRENTWOOD, TN / ACCESSWIRE / November 28, 2023 / Odyssey Behavioral Healthcare, a leading provider of mental health, eating disorder,…

4 months ago

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,…

4 months ago

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite…

4 months ago